Skip to main navigation
AC Immune - World-class science that makes a difference in  patients' lives
  • About Us
    About us Our Teams Our Partners Our R&D Strategy
  • Our Science
    Our Science Pioneering Precision Medicine Technology Platforms Scientific Publications
  • Our Pipeline
    Our Pipeline Therapeutic Focus Clinical Trials
  • Investors
  • Careers
    Careers Join us
Investors
  • Why Invest
  • Key Figures
  • Share Price
  • Analyst Coverage
  • Milestones
  • Key Shareholders
  • FAQ
Press Releases
In the News
Events & Presentations
Corporate Governance
Financial Reporting
Contacts & Resources
search

Press Releases

  1. Home
  2. Investors
  3. Press Releases

PRESS RELEASES

 
Date Title View
Jun 24, 2022 AC Immune Holds Annual General Meeting of Shareholders
Jun 16, 2022 AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
May 31, 2022 AC Immune to Present at the 2022 Jefferies Healthcare Conference
May 17, 2022 AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award
May 09, 2022 AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology
Apr 28, 2022 AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update
Apr 27, 2022 AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference
Apr 08, 2022 AC Immune Reports Changes to Senior Management
Mar 30, 2022 AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases
Mar 22, 2022 AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »

Shareholder Tools

Print Page
Print Page
Email Alerts
Email Alerts
Information Request
Information Request
Contact IR
Contact IR

AC Immune SA

EPFL Innovation Park-Building B 1015 Lausanne / Switzerland
  • Phone: +41 21 345 91 21
  • Fax: +41 21 345 91 20
  • Email: info@acimmune.com
  • Home
  • About Us
  • Our Science
  • Our Pipeline
  • Investors
  • Careers

Stay in touch

Get to know us

Social Links (Redesign)

© 2022 AC Immune SA

Legal Links (Redesign)

  • Privacy policy
  • Supplier information
  • Terms of use